DAX24.178 -0,2%ESt505.399 -0,3%Top 10 Crypto14,46 -1,7%Dow42.344 +1,8%Nas19.199 +2,5%Bitcoin96.176 ±0,0%Euro1,1338 ±0,0%Öl64,35 +0,1%Gold3.323 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 RENK RENK73 HENSOLDT HAG000 Tesla A1CX3T BYD A0M4W9 Siemens Energy ENER6Y Lufthansa 823212 Bayer BAY001 D-Wave Quantum A3DSV9 thyssenkrupp 750000 Deutsche Bank 514000 Infineon 623100 BASF BASF11 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
NVIDIA vor Bilanz: DAX nach Rekord tiefer -- Asiens Börsen uneins -- Aktien von Foxconn, SK Hynix, Samsung Electronics & Co. legen zu -- Quantum eMotion, AMD, Rheinmetall, HENSOLDT, RENK im Fokus
Top News
RWE-Aktie fester: Urteil in Klimaklage steht bevor RWE-Aktie fester: Urteil in Klimaklage steht bevor
UniCredit erhöht Anteil an Alpha Bank - Weitere Aufstockung geplant - Aktie steigt UniCredit erhöht Anteil an Alpha Bank - Weitere Aufstockung geplant - Aktie steigt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Handeln
Aktien-Sparplan anlegen
107,35 EUR +0,25 EUR +0,23 %
STU
122,66 USD +2,56 USD +2,13 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.10,72 Mrd. EUR

KGV41,47Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
PR NewswireNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY...
Wer­bungNeurocrine Biosciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improv...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in May
PR NewswireNeurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
BenzingaWhat 19 Analyst Ratings Have To Say About Neurocrine Biosciences
ZacksNeurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
PR NewswireNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
PR NewswireNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
PR NewswireNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
ZacksNeurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
PR NewswireNeurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of C...
BenzingaWhat 16 Analyst Ratings Have To Say About Neurocrine Biosciences
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
ZacksImplied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
PR NewswireNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
PR NewswireNeurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
MotleyFoolNeurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
BenzingaDeep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)
PR NewswireNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
PR NewswireNeurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR NewswireNeurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements i...
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in March
BenzingaAssessing Neurocrine Biosciences: Insights From 15 Financial Analysts
PR NewswireNeurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
MotleyFoolWhy Neurocrine Biosciences Stock Sank Today
BenzingaWhy Is Neurocrine Biosciences Stock Trading Lower On Friday?
MotleyFoolNeurocrine Biosciences Reports Mixed Q4
ZacksNeurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
BenzingaEarnings Summary: Neurocrine Biosciences Q4
PR NewswireNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
BenzingaNeurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
ZacksNeurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
PR NewswireNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Wer­bung

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.